[go: up one dir, main page]

AR077520A1 - Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal - Google Patents

Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal

Info

Publication number
AR077520A1
AR077520A1 ARP080105632A ARP080105632A AR077520A1 AR 077520 A1 AR077520 A1 AR 077520A1 AR P080105632 A ARP080105632 A AR P080105632A AR P080105632 A ARP080105632 A AR P080105632A AR 077520 A1 AR077520 A1 AR 077520A1
Authority
AR
Argentina
Prior art keywords
oligosaccharides
intestinal microbiota
sphymphyelin
digerable
carbohydrates
Prior art date
Application number
ARP080105632A
Other languages
English (en)
Inventor
Jan Knol
Christopher Beermann
Guenther Boehm
Willem F Nieuwenhuizen
Der Been Eline Marleen Van
Amor Kaouther Ben
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40801379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of AR077520A1 publication Critical patent/AR077520A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pediatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicacion 1: Uso de una composicion nutricional que comprende: A esfingofosfolípidos, preferiblemente esfingomielina, y/o al menos un producto de degradacion de esfingofosfolípidos seleccionado del grupo que consiste en ceramida, lisoesfingofosfolípidos, fosfatos esfingoides, y bases esfingoides libres, y B al menos un carbohidrato no digerible seleccionado del grupo que consiste en fructo-oligosacáridos, galacto-oligosacáridos, gluco-oligosacáridos, arabino-oligosacáridos, manano-oligosacáridos, xilo-oligosacáridos, fuco-oligosacáridos, arabinogalacto-oligosacáridos, glucomano-oligosacáridos, galactomano-oligosacáridos, oligosacáridos que comprenden ácido siálico y oligosacáridos de ácido uránico para fabricar una composicion para normalizar la microbiota intestinal en un sujeto humano, para obtener una microbiota similar a la hallada en sujetos delgados saludables y/o lactantes alimentados con leche materna.
ARP080105632A 2007-12-21 2008-12-19 Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal AR077520A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07124007 2007-12-21
US4078808P 2008-03-31 2008-03-31
EP08153775 2008-03-31

Publications (1)

Publication Number Publication Date
AR077520A1 true AR077520A1 (es) 2011-09-07

Family

ID=40801379

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080105632A AR077520A1 (es) 2007-12-21 2008-12-19 Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal
ARP080105631A AR071550A1 (es) 2007-12-21 2008-12-19 Uso de carbohidratos no digeribles para mejorar la microbiota intestinal

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080105631A AR071550A1 (es) 2007-12-21 2008-12-19 Uso de carbohidratos no digeribles para mejorar la microbiota intestinal

Country Status (8)

Country Link
US (2) US20110009359A1 (es)
EP (3) EP2229063A1 (es)
CN (2) CN101951794B (es)
AR (2) AR077520A1 (es)
ES (2) ES2402687T3 (es)
PL (2) PL2589302T3 (es)
RU (2) RU2478309C2 (es)
WO (2) WO2009082214A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695427B (zh) * 2009-08-18 2016-04-13 雀巢产品技术援助有限公司 包含乳球菌属菌株并且特别是在婴儿和儿童中减少过敏症状的营养组合物
SG191395A1 (en) 2010-12-31 2013-08-30 Abbott Lab Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
EP2514435A1 (en) * 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
JP5877902B2 (ja) 2011-08-17 2016-03-08 マイクロバイオーム セラピューティクス，エルエルシー バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用
JP5827519B2 (ja) * 2011-08-25 2015-12-02 株式会社ダイセル ペルオキシソーム増殖剤応答性受容体活性化剤
WO2013062402A1 (en) * 2011-10-24 2013-05-02 N.V. Nutricia Allergy treatment with non- digestible oligosaccharide
SG11201403712XA (en) * 2011-12-27 2014-10-30 Abbott Lab Use of reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
JP6169978B2 (ja) * 2012-01-25 2017-07-26 株式会社Ｊ−オイルミルズ スフィンゴイド塩基を含む抽出物の製造方法
AU2012369298B2 (en) * 2012-02-10 2016-02-25 N.V. Nutricia Maternal supplement to enhance immune system of an infant
WO2013126015A1 (en) * 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
SE536599C3 (sv) * 2012-04-10 2017-01-10 Hero Ag Näringssammansättning med lågt kalori- och lågt proteininnehåll
CN104968216A (zh) * 2012-12-10 2015-10-07 N·V·努特里奇亚 含有非消化性寡糖的营养组合物
US10028519B2 (en) * 2014-03-05 2018-07-24 Mead Johnson Nutrition Company Nutritional compositions containing ceramide and uses thereof
MY186844A (en) 2014-07-09 2021-08-25 Cadena Bio Inc Oligosaccharide compositions and methods for producing thereof
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
ES2938746T3 (es) 2015-01-26 2023-04-14 Dsm Nutritional Products Llc Composiciones de oligosacáridos para el uso como alimento para animales y sus métodos para producirlas
MX381376B (es) 2015-01-26 2025-03-12 Kaleido Biosciences Inc Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
MX2017013562A (es) * 2015-04-23 2018-05-28 Kaleido Biosciences Inc Reguladores de microbioma y usos relacionados de los mismos.
EP3964234A1 (en) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
EP3331534B1 (en) 2015-08-04 2019-12-18 Société des Produits Nestlé S.A. Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants
CN108348536B (zh) 2015-11-17 2021-09-24 格礼卡姆股份公司 治疗抗生素相关性并发症的合成组合物
EP4233904A3 (en) 2015-12-14 2024-01-10 Société des Produits Nestlé S.A. Compositions and their use
WO2017103850A1 (en) 2015-12-15 2017-06-22 Glycom A/S Mixture of hmos
MY186314A (en) * 2016-01-26 2021-07-08 Nestle Sa Compositions comprising 2fl and lnnt to control food intake and growth in infants or young children
EP3471562A4 (en) * 2016-06-15 2020-07-29 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
WO2018024440A1 (en) * 2016-08-04 2018-02-08 Nestec Sa Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea
US11273186B2 (en) 2017-08-29 2022-03-15 Bgi Shenzhen Application of bacteroides cellulosityticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
TWI816735B (zh) * 2018-01-18 2023-10-01 日商朝日集團控股股份有限公司 酵母甘露聚糖之用途
EP3749328A1 (en) * 2018-02-09 2020-12-16 N.V. Nutricia Fermented formula with non-digestible oligosaccharides
CA3109600A1 (en) 2018-08-21 2020-02-27 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof for reducing ammonia levels
CA3118909A1 (en) 2018-11-08 2020-05-14 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof
EP3911179A2 (en) * 2019-01-18 2021-11-24 CP Kelco U.S., Inc. Prebiotic composition and its use
AU2021212325A1 (en) * 2020-01-31 2022-07-28 N.V. Nutricia Nutritional composition for use in gut maturation
KR102236944B1 (ko) * 2020-04-29 2021-04-06 (주)네오크레마 갈락토올리고당, 또는 갈락토올리고당 및 콜라겐 트리펩타이드를 포함하는 면역기능 개선 및 피부상태 개선용 기능성 식품조성물 및 화장료 조성물
CN113476463A (zh) * 2021-07-13 2021-10-08 量子高科(广东)生物有限公司 一种益生元组合物及其应用
EP4586830A1 (en) 2022-09-14 2025-07-23 N.V. Nutricia Nutritional composition
EP4586831A1 (en) 2022-09-14 2025-07-23 N.V. Nutricia Nutritional composition
EP4654836A1 (en) 2023-01-27 2025-12-03 N.V. Nutricia Nutritional composition for improving gut microbiota

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4008974B2 (ja) * 1996-12-12 2007-11-14 森永乳業株式会社 ビフィズス菌増殖促進組成物及びその用途
DE19836339B4 (de) * 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
JP3544493B2 (ja) * 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
EP1062873A1 (en) * 1999-12-13 2000-12-27 N.V. Nutricia Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate
EP1175905A1 (en) * 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Nutritional Composition
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
EP1438933B1 (de) * 2003-01-17 2005-04-06 WALDEMAR LINK GmbH & Co. KG Hüftprothese mit einem in den Markkanal des Oberschenkelknochens zu verankernden Schaft
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
EP1670934B1 (en) 2003-10-02 2008-10-29 Nestec S.A. Prebiotic effect analysis
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
CN104223094A (zh) * 2005-02-28 2014-12-24 纽崔西亚公司 具有益生菌的营养组合物
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
BRPI0620451A2 (pt) * 2005-12-23 2011-04-12 Nutricia Nv uso de uma composição compreendendo um lipìdeo, proteìna e componente de carboidrato digerìvel
EP1803358A1 (en) 2005-12-28 2007-07-04 Laboratorios Ordesa, S.L Infant immunological formula

Also Published As

Publication number Publication date
PL2589302T3 (pl) 2017-05-31
EP2589302A1 (en) 2013-05-08
EP2229063A1 (en) 2010-09-22
EP2234505A1 (en) 2010-10-06
ES2402687T3 (es) 2013-05-07
AR071550A1 (es) 2010-06-30
US20110034407A1 (en) 2011-02-10
RU2010130468A (ru) 2012-01-27
RU2608215C2 (ru) 2017-01-17
RU2012155333A (ru) 2014-06-27
RU2478309C2 (ru) 2013-04-10
CN101951794A (zh) 2011-01-19
WO2009082216A1 (en) 2009-07-02
PL2234505T3 (pl) 2013-06-28
EP2234505B1 (en) 2013-01-30
US20110009359A1 (en) 2011-01-13
WO2009082214A1 (en) 2009-07-02
EP2589302B1 (en) 2016-11-23
CN101945589A (zh) 2011-01-12
CN101951794B (zh) 2016-11-02
ES2611203T3 (es) 2017-05-05

Similar Documents

Publication Publication Date Title
AR077520A1 (es) Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal
Palaniappan et al. Current status of xylooligosaccharides: Production, characterization, health benefits and food application
PH12015500904B1 (en) Synbiotics combination for brain improvement
WO2009050580A8 (fr) Composition destinee a la regulation du metabolism des lipides
AR054257A1 (es) Suplemento nutricional para pacientes con hiv
JP2013224310A5 (es)
AR067020A1 (es) Alimento nutritivo con bifidobacteria no viable y oligosacarido no digerible
HK1214090A1 (zh) 含有神经组分的营养组合物及其用途
BR112015029911A2 (pt) bolo alimentar líquido coesivo compreendendo moléculas que fornecem viscoelasticidade
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
AR056313A1 (es) Inulina de cadena larga
Tsutaya et al. Isotopic evidence of dietary variability in subadults at the Usu-moshiri site of the Epi-Jomon culture, Japan
MA35891B1 (fr) Procédé de préparation d'un produit sirupeux comprenant des vitamines
MX380334B (es) Cepas de lactococcus lactis y preparaciones bacterianas de las mismas, para la produccion de peptidos bioactivos que tienen efectos antihipertensivos y de disminucion de colesterol en mamiferos; productos nutricionales y terapéuticos producidos a partir de los mismos.
GB2510712A (en) Nutritional product comprising a biguanide
JP6948774B2 (ja) ウロリチン類を含有する前駆脂肪細胞分化抑制剤
IT1391032B1 (it) Biomassa arricchita in rame, procedimento per la sua preparazione e prodotti probiotici, cosmetici, dietetici e nutraceutici comprendenti tale biomassa
Souza et al. Fibroblast Viability after Storage at 20° C in Milk, Hank's Balanced Salt Solution and Coconut Water
JP2012065607A (ja) サプリメント
AR068238A1 (es) Alimentos no perecederos para ninos que solo incluyen azucares "contenidos naturalmente " y metodos para la fabricacion de los mismos
US20200281245A1 (en) Human milk fortifier
Akiduki et al. A single-blind, parallel trial of l-hydroxyproline in healthy adult subjects
van den Heuvel et al. Lactulose Stimulates Calcium Absorption in Postmenopausal Women Dose-Dependently
NZ747942A (en) Synbiotics combination for brain improvement
ES2832552T3 (es) Administración materna de vitamina B12 para la prevención del aumento de adiposidad, sobrepeso u obesidad en la descendencia especialmente en la descendencia de madres con sobrepeso y/u obesidad

Legal Events

Date Code Title Description
FB Suspension of granting procedure